All Stories

  1. Reply to: Tariq N, Awais Amir, M. Letter to Editor: Methodological considerations regarding smoking, psychological distress, and medication-overuse headache
  2. Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  3. Smoking and medication-overuse headache: Exploring the potential link between nicotine dependence and analgesic overuse
  4. Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990–2023: a Global Burden of Disease study
  5. Global burden of adverse effects of medical treatment from 1990 to 2021: a Global Burden of Disease Study 2021
  6. Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  7. Headache with Neurological Deficits and CSF Lymphocytosis (HaNDL Syndrome)
  8. Global, regional, and national burden of headache disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  9. Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  10. Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trials
  11. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
  12. Global, regional, and national burden of headache disorders, 1990–2021, with forecasts to 2050: A Global Burden of Disease study 2021
  13. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  14. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  15. The global, regional, and national burden attributable to low bone mineral density, 1990–2020: an analysis of a modifiable risk factor from the Global Burden of Disease Study 2021
  16. GBD 2023 Cardiovascular Disease Collaborators
  17. GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis
  18. Ramadan fasting in smokers with primary headache disorders: Impact of nicotine dependence on headache frequency and severity
  19. Secondary Macular Hole Closure With Sub-Tenon Triamcinolone Acetonide
  20. Reliability and validity of the Arabic version of cluster headache impact questionnaire in both active episodic and chronic cluster headache
  21. Characterising acute and chronic care needs: insights from the Global Burden of Disease Study 2019
  22. Efficacy of robotic training gloves in improving hand function and movement in stroke patients
  23. Multimodal diagnostic tools and advanced data models for detection of prodromal Parkinson’s disease: a scoping review
  24. Global, regional, and national burden of epilepsy, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  25. Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
  26. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021
  27. Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021
  28. Epilepsy Arabic renaming to cerebroelectric disorder could minimize the stigma
  29. Validity, reliability, and sensitivity to change of the Arabic version of the Migraine‐Specific Quality‐of‐Life Questionnaire after prophylactic treatment
  30. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021
  31. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
  32. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
  33. The burden of neurological conditions in north Africa and the Middle East, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
  34. Unveiling the retinal secrets of neuromyelitis optica spectrum disorder
  35. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  36. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a syst...
  37. Burden of disease scenarios for 204 countries
  38. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  39. Reliability, validity, and responsiveness of the Arabic version of HIT ‐6 questionnaire in patients with migraine indicated for preventive therapy: A multi‐center study
  40. Global Health Trends 1950–2021: Impact of COVID-19 on Mortality and Population Growth
  41. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
  42. Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021
  43. Validity and reliability of Arabic version of pediatric migraine disability assessment scale (Child Self-Report versus Parent Proxy-Report): a multi-center study
  44. The significance of miRNA-191-5P and miRNA-24-3P as novel biomarkers for multiple sclerosis: a case–control study
  45. Global Burden of Cardiovascular Diseases and Risks, 1990-2022
  46. Vision Impairment prediction for patients diagnosed with Multiple Sclerosis: Cosmos based machine learning model training and evaluation
  47. Global, regional, and national burden of spinal cord injury, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  48. Global, regional, and national incidence of six major immune-mediated inflammatory diseases: findings from the global burden of disease study 2019
  49. The burden of metabolic risk factors in North Africa and the Middle East, 1990–2019: findings from the Global Burden of Disease Study
  50. Clinical Predictors of Transation to Secondary Progressive Multiple Sclerosis
  51. Neutrophil-to-Lymphocyte Ratio: a Marker of Neuro-inflammation in Multiple Sclerosis Patients: a Meta-analysis and Systematic Review
  52. Impact of nutrition counseling on anthropometry and dietary intake of multiple sclerosis patients at Kasr Alainy Multiple Sclerosis Unit, Cairo, Egypt 2019–2020: randomized controlled clinical trial
  53. Amelioration of bioavailability through formulating and optimizing Azilsartan Entrapped nanostructured lipid carriers and its pharmacokinetic assessment
  54. Comparative study of the anti-diabetic effect of mucilage and seed extract of Abelmoschus esculentus against streptozotocin-induced diabetes in rat model
  55. Screening, molecular simulation & in silico kinetics of virtually designed covid-19 main protease inhibitors
  56. Lagerstroemia speciosa Ameliorated Blood Pressure in LNAME Induced Hypertension in Experimental Rats through NO/cGMP and Oxidative Stress Modulation
  57. An in-silico investigation of potential natural polyphenols for the targeting of COVID main protease inhibitor
  58. Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019
  59. Nanotechnological Advances in the Treatment of Epilepsy
  60. Board Walk
  61. Injury burden in individuals aged 50 years or older in the Eastern Mediterranean region, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019
  62. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study
  63. Helicobacter pylori infection in migraine headache: A true association or an innocent bystander?
  64. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
  65. Neurological Manifestations in a Cohort of Egyptian Patients with COVID-19: A Prospective, Multicenter, Observational Study
  66. In Vitro Evaluation of Antibacterial, Antioxidant, and Antidiabetic Activities and Glucose Uptake through 2‐NBDG by Hep‐2 Liver Cancer Cells Treated with Green Synthesized Silver Nanoparticles
  67. Impact of Ramadan fasting on disease activity in patients with multiple sclerosis: a multicenter study
  68. Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study
  69. The MuSC-19 study: The Egyptian cohort
  70. Mapping Anemia in Women: Global Trends and Inequality
  71. Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019
  72. Behavior and awareness of multiple sclerosis patients during COVID-19 pandemic in a tertiary center in Egypt
  73. MicroRNA-22 Level in Patients with Multiple Sclerosis and Its Relationship with Vitamin D and Vitamin D Receptor Levels
  74. Zinc deficiency correlates with severity of diabetic polyneuropathy
  75. Child Mortality Trends and Targets: GBD 2019 Findings
  76. Mapping inequalities in exclusive breastfeeding in low- and middle-income countries, 2000–2018
  77. Physical and Mental Fatigue in Subjects Recovered from COVID-19 Infection: A Case–Control Study
  78. Reliability and validity of Arabic version of the brief international cognitive assessment for multiple sclerosis: Egyptian dialect
  79. Bovine mastitis prevention and control in the post-antibiotic era
  80. lincR-Ccr2-5′AS and THRIL as potential biomarkers of multiple sclerosis
  81. The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt
  82. Co-Occurrence of Guillain-Barre Syndrome and Multiple Sclerosis: A Rare Case Report
  83. Global mortality from dementia: Application of a new method and results from the Global Burden of Disease Study 2019
  84. The Burden of Dementia due to Down Syndrome, Parkinson’s Disease, Stroke, and Traumatic Brain Injury: A Systematic Analysis for the Global Burden of Disease Study 2019
  85. The potential role of 2D-speckle tracking echocardiography for detecting left ventricular systolic dysfunction in patients with Parkinson’s disease: a case control study
  86. Five insights from the Global Burden of Disease Study 2019
  87. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  88. FOXP3 rs3761548 gene variant and interleukin-35 serum levels as biomarkers in patients with multiple sclerosis
  89. Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era
  90. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  91. Crystal Growth and Kinetic Behaviour of Pseudoalteromonas espejiana Assisted Biosynthesized Gold Nanoparticles
  92. Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach
  93. Interferon-Beta-Induced Headache in Patients with Multiple Sclerosis: Frequency and Characterization
  94. Glutamate and Nitric Oxide as biomarkers for disease activity in patients with multiple sclerosis
  95. Impact of insulin resistance and metabolic syndrome on disability in patients with multiple sclerosis
  96. Thalamic Involvement and its Impact on Disability and Cognition in Multiple Sclerosis: A Clinical and Diffusion Tensor Imaging Study
  97. Assessment of School-Aged Children of Mothers With Idiopathic Generalized Epilepsy
  98. Evaluating optic nerve diameter as a possible biomarker for disability in patients with multiple sclerosis
  99. Foot-and-mouth disease vaccines: recent updates and future perspectives
  100. Proprioception Errors in Patients with Cervical Spondylosis at Sagittal Plane
  101. Diffusivity Parameters as Markers for NAGM Involvement and Disease Progression in MS Patients: Diffusion Tensor Imaging Study
  102. Testing of Verbal Fluency in Egyptians
  103. Role of concentric needle Single Fiber Electromyography in detection of subclinical motor involvement in carpal tunnel syndrome
  104. Pediatric-onset multiple sclerosis in Egypt: a multi-center registry of 186 patients
  105. Objective pain assessment by electrical stimulation
  106. Clinical, diffusion tensor imaging, and cognitive biomarkers of seizure control in patients with juvenile myoclonic epilepsy
  107. Verbal fluency tests in Egyptians: Cultural and educational challenges
  108. P295 Effects of functional electric stimulation and task specific training on gait recovery in patients with stroke: Randomized controlled trial
  109. Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study
  110. Urinary 6-Sulphatoxymelatonin Levels and Sleep Disorders in Children With Migraine